OBJECTIVE: To review the challenges of designing behavioral and biological outcome measures for the multinational NIMH Collaborative HIV/STD Prevention Trial and provide the rationale for selecting these measures. DESIGN: Although many different evidence-based prevention programmes have been developed, few have been evaluated in different countries, cultures, and populations. One issue in evaluating the generalized efficacy of any prevention approach is to identify a set of common outcome measures useful across diverse settings and peoples. The Trial is designed to evaluate whether the community popular opinion leader intervention can be adapted cross-nationally and cross-culturally for different populations and still retain its efficacy. METHODS: Literature reviews, investigator experience, ethnographic study, pilot studies, and epidemiological studies were used to select the endpoints for the Trial. RESULTS AND CONCLUSION: Both biological and behavioral data will be obtained at baseline and 12 and 24 months post-baseline. Communities that receive the intervention will be compared with matched control communities on two primary outcomes: (i) a change in self-reported unprotected sexual acts with non-spousal, non-live-in partners; and (ii) the incidence of sexually transmitted disease (STD), defined as a composite index of viral and bacterial STD.
OBJECTIVE: To review the challenges of designing behavioral and biological outcome measures for the multinational NIMH Collaborative HIV/STD Prevention Trial and provide the rationale for selecting these measures. DESIGN: Although many different evidence-based prevention programmes have been developed, few have been evaluated in different countries, cultures, and populations. One issue in evaluating the generalized efficacy of any prevention approach is to identify a set of common outcome measures useful across diverse settings and peoples. The Trial is designed to evaluate whether the community popular opinion leader intervention can be adapted cross-nationally and cross-culturally for different populations and still retain its efficacy. METHODS: Literature reviews, investigator experience, ethnographic study, pilot studies, and epidemiological studies were used to select the endpoints for the Trial. RESULTS AND CONCLUSION: Both biological and behavioral data will be obtained at baseline and 12 and 24 months post-baseline. Communities that receive the intervention will be compared with matched control communities on two primary outcomes: (i) a change in self-reported unprotected sexual acts with non-spousal, non-live-in partners; and (ii) the incidence of sexually transmitted disease (STD), defined as a composite index of viral and bacterial STD.
Authors: Linda B Cottler; Veena A Satyanarayana; Catina C O'Leary; Krishna Vaddiparti; Vivek Benegal; Prabha S Chandra Journal: AIDS Behav Date: 2010-08
Authors: R Scott McClelland; Barbra A Richardson; George H Wanje; Susan M Graham; Esther Mutunga; Norbert Peshu; James N Kiarie; Ann E Kurth; Walter Jaoko Journal: Sex Transm Dis Date: 2011-05 Impact factor: 2.830
Authors: Vivian F Go; Aylur K Srikrishnan; Megan L Salter; Shruti Mehta; Sethulakshmi C Johnson; Sudha Sivaram; Wendy Davis; Suniti Solomon; David D Celentano Journal: Soc Sci Med Date: 2010-08-06 Impact factor: 4.634
Authors: Roger Detels; Annette M Green; Jeffrey D Klausner; David Katzenstein; Charlotte Gaydos; H Hunter Handsfield; Willo Pequegnat; Kenneth Mayer; Tyler D Hartwell; Thomas C Quinn Journal: Sex Transm Dis Date: 2011-06 Impact factor: 2.830
Authors: Hayoung Park; Kelika A Konda; Chelsea P Roberts; Jorge L Maguiña; Segundo R Leon; Jesse L Clark; Thomas J Coates; Carlos F Caceres; Jeffrey D Klausner Journal: PLoS One Date: 2016-09-07 Impact factor: 3.240